Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Dr. Koffman’s Bispecific T-cell Engager (epcoritamab) Trial for CLL Blog

Despite an aggressive flavor of CLL, I enjoyed a 7+ year remission from my PCI-32765 (now known as ibrutinib), phase 1 trial, and 5+ years from my JCAR-014 (the parent of liso-cel) phase 1 trial. Now I am hoping that I get a similar response from my epcoritamab (EPCORE™) trial with this new bispecific T cell engaging monoclonal. Join and learn with me as I blog about my experiences.